Company Participants Conference Call Participants Operator Leandro Mazzoni Roy, over to you. Secondly, we have taken several very important steps in resolving the consequences of the Respironics recall. The consent decree was signed and approved in court. We received final court approval for the previously announced economic loss settlement. We reached an agreement to resolve the personal injury and medical monitoring litigation in U.S. And we also concluded an agreement with insurers to cover Respironics r ...

Washington, D.C. 20549 Form 20-F (Mark one) a REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 As filed with the Securities and Exchange Commission on February 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ® ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ロ SHELL COMPANY REP ...

Financial Performance - Sales reached EUR 18.2 billion with an adjusted EBITA margin of 10.6%[16] - Free cash flow amounted to EUR 1,582 million, indicating strong cash generation[16] - Total revenues from goods sold amounted to EUR 12.4 billion[69] - Comparable sales growth was reported at 6.0%[75] - Group sales increased by 6% on a comparable basis to EUR 18.2 billion in 2023, with a nominal sales growth of 2%[188] - Adjusted EBITA rose to EUR 1,921 million, representing 10.6% of sales, compared to 7.4% in 2022, driven by increased sales and productivity measures[191] - Operating cash flow improved significantly to EUR 2,136 million, compared to an outflow of EUR 173 million in 2022[188] - Net income for 2023 was a loss of EUR 463 million, an improvement from a loss of EUR 1.6 billion in 2022, influenced by a EUR 575 million provision related to Respironics litigation[191] Strategic Initiatives - A strategic investment by Exor resulted in a 15% minority stake in the company, signaling confidence in its future[30] - The company is on track to reduce 10,000 roles by 2025, with 8,000 roles already eliminated[29] - The company is implementing a simplified operating model to remain competitive in an inflationary environment[64] - The company is concentrating resources on areas with strong positions for accelerated growth, such as Image Guided Therapy and Personal Health[55] - The company plans to consolidate its R&D locations into a new hub in Bangalore, India, hosting around 5,000 employees[184] Sustainability and Environmental Commitment - Circular revenues accounted for 20% of total sales, highlighting a commitment to sustainability[15] - The company aims to achieve 'Zero Waste to Landfill' across all industrial sites by year-end 2023[76] - The company is collaborating with customers and suppliers to decarbonize healthcare and create a more sustainable industry[36] - Philips has entered into several power purchase agreements to meet its long-term Science Based Targets and reduce full value chain emissions in line with a 1.5°C global warming scenario[200] - The company achieved a reduction in CO₂ emissions to 22 kilotons in 2023, surpassing its target of 35 kilotons[185] Product and Market Development - Approximately 40% of revenues are recurring, reflecting a stable revenue base[14] - Approximately 48% of revenues came from new products and solutions introduced in the last three years[76] - 70.5% of revenues were generated from Green/EcoDesigned products[75] - The Diagnosis & Treatment segment accounted for 49% of total sales[89] - The Connected Care segment generated total sales with Monitoring at 60%, Sleep & Respiratory Care at 17%, and Enterprise Informatics at 23% in 2023[109] - Philips launched the MR 7700 3.0T system and Spectral CT 7500 imaging system, enhancing diagnostic capabilities in over 10,000 hospital beds in Shanghai[100] - Philips expanded its ultrasound portfolio with the launch of the Ultrasound Compact 5500 CV, enhancing bedside care for cardiology and vascular patients[101] Customer Engagement and Brand Strength - Philips' Pregnancy+ app has over 1.5 million daily active users and was ranked among the best pregnancy apps of 2023 by Forbes[123] - Philips' brand strength increased in China, with significant growth in Male Grooming and Oral Healthcare, solidifying leadership positions despite a weak consumer market[155] - The partnership with Babybell Maternal & Child Supplies aims to accelerate growth of the Philips Avent brand in China, leveraging local market understanding[130] - Philips Sonicare remains the leading electric rechargeable toothbrush brand in the US and Canada, while Philips Norelco leads in electric male grooming[150] Operational Challenges and Improvements - Order intake showed a decline, prompting necessary improvement actions[22] - The Sleep & Respiratory Care business faced operational challenges but is gradually returning to the market for sleep therapy devices outside the US[105] - Limited availability and delays in the supply of certain components and products impacted results in 2022, leading to increased overall working capital, particularly inventories[197] - The geopolitical environment, including the situation in the Middle East, increases economic and political uncertainty for the company's global operations[199] Innovation and Research - The company invested EUR 1.9 billion in R&D, with EUR 142 million specifically for Green/EcoDesigned Innovation[74] - New patent filings totaled 795, generating royalties of EUR 434.2 million[75] - Philips won 160 awards for design excellence in 2023, highlighting its commitment to innovation and customer experience[136] - The Enterprise Monitoring as a Service model (EMaaS) has enabled health systems to standardize patient monitoring platforms, enhancing patient safety and outcomes[149]

• Increased sales, pricing and productivity measures, partly offset by cost inflation • Includes ~150 million cash outflow related to resolution of the economic loss class action EUR 1.6 billion Improved operational performance across business segments *) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree Confident in delivering the plan for 2023-2025, with further Preferred strategic and innovation partner for customers as of January ...

Koninklijke Philips N.V. (NYSE:PHG) Q4 2023 Earnings Conference Call January 29, 2024 4:00 AM ET Company Participants Leandro Mazzoni - Head-Investor Relations Roy Jakobs - Chief Executive Officer Abhijit Bhattacharya - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays David Adlington - JPMorgan Richard Felton - Goldman Sachs Veronika Dubajova - Citi Lisa Clive - Bernstein Graham Doyle - UBS Sezgi Ozener - HSBC Julien Dormois - Jefferies Leandro Mazzoni Hi, everyone. Welcome t ...

Koninklijke Philips N.V (NYSE:PHG) Q3 2023 Earnings Call Transcript October 23, 2023 4:00 AM ET Conference Call Participants I will now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir. I would like to hand over to Roy. We continue to see hospital healthcare systems in the US and other mature geographies exhibit cautious buying behavior in the short term, and China is heavily impacted by the government-initiated anti-corruption measures. But I look at the fut ...

Philips has recognized a provision related to the voluntary recall notification in the US/field safety notice outside the US for certain sleep and respiratory care products, based on Philips' best estimate for the expected field actions. Future developments are subject to significant uncertainties, which require management to make estimates and assumptions, about items such as quantities and the portion to be replaced or repaired. Actual outcomes in future periods may differ from these estimates and affect ...

October 23, 2023 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 KONINKLIJKE PHILIPS N.V. (Exact name of registrant as specified in its charter) Royal Philips (Translation of registrant's name into English) The Netherlands (Jurisdiction of incorporation or organization) Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands (Address of principal executive offices) Indicate by chec ...

Koninklijke Philips N.V. (NYSE:PHG) Q2 2023 Earnings Conference Call July 24, 2023 4:00 AM ET Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Richard Felton - Goldman Sachs David Adlington - JPMorgan Robert Davies - Morgan Stanley Graham Doyle - UBS Sezgi Bice Ozener - HSBC Falko Friedrichs - Deutsche Bank I will now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir. With that, I would like to hand over to Roy. Thirdly, resolving the Respironics recall fo ...

Reduction of 10k roles Examples of our progress in Q2 2023 Towards a reliable end-to-end supply chain Simplified, more agile operating model 22 (in millions of EUR unless otherwise stated) Group inventories | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------|---------|---------|---------|---------|-----------|---------|-------|---------|---------|---------|-------|---------------|----------|-------------------|---------|----- ...